AI to Support Prostate Cancer Diagnosis
Featuring Paige Prostate Detect, the first and only FDA-approved AI in pathology*
Diagnostic ai
A comprehensive suite of AI applications to support pathologists in the detection & diagnosis of prostate cancer
The Paige Prostate Suite is comprised of Paige Prostate Detect, Paige Prostate Grade & Quantify, and Paige Prostate Perineural Invasion, making it the most robust set of AI applications available to assist in the review of scanned whole–slide images from prostate needle biopsies prepared with hematoxylin & eosin (H&E).
The applications within the Suite work alongside a comprehensive standard of care conducted by the pathologist. This gives pathologists the capability to improve efficiency and enhance diagnostic confidence for difficult cases. Our prostate AI applications accomplish this by identifying suspicious regions of interest, automatically measuring the length and percentage of tumor, prioritizing case review, and providing quality assurance
A complete solution for detecting and grading prostate cancer
Ground-Breaking Technology
Paige Prostate Detect is the first and currently only FDA-Approved AI in Pathology*
Paige’s applications were trained on tens of thousands of whole-slide images from hundreds of sites around the world and validated in numerous independent studies1-4
Developed with over 55,000 whole-slide images from over 1,000 institutions around the world, using various tissue preparation, staining, and storage techniques.
Validated with data from over 200 institutions in 5 countries and 22 states across diverse and representative ethnicities.
Sensitivity and specificity tuned to overlook common mimickers that pathologists prefer AI not to highlight, such as high grade prostatic intraepithelial neoplasia.
Consistently perform regardless of image type, staining technique, or other pre-analytical variations
No on-site validation or calibration required
AI results immediately available
Independently validated and clinically utilized
Trusted by leading healthcare providers around the world for use in routine practice
Results
The post-signout AI use identified one false negative result
6 of 210 cases were flagged for review, improving quality assurance process
Paige Prostate provided 100% Sensitivity
Backspecificity2
sensitivity2
reduction in cancer detection errors4
reduction in time to diagnosis3
Ready to discover how Paige can transform your lab?
Schedule a personalized product demonstration with one of our specialists
Experience the future of pathology, today
Sign up for a free 30-day trial of the Paige Breast Suite or other AI applications
- 1Eloy, Catarina et al. “Artificial intelligence-assisted cancer diagnosis improves the efficiency of pathologists in prostatic biopsies.” Virchows Archiv : an international journal of pathology vol. 482,3 (2023): 595-604. doi:10.1007/s00428-023-03518-5
- 2Perincheri, S., Levi, A.W., Celli, R. et al. “An independent assessment of an artificial intelligence system for prostate cancer detection shows strong diagnostic accuracy.” Mod Pathol 34, 1588–1595 (2021)
- 3da Silva, Leonard M., et al. “Independent real-world application of a clinical-grade automated prostate cancer detection system.” Journal of Pathology 254.2 (2021): 147-158
- 4Raciti, Patricia., Sue, Jillian., et al. “Clinical Validation of Artificial Intelligence Augmented Pathology Diagnosis Demonstrates Significant Gains in Diagnostic Accuracy in Prostate Cancer Detection.” Archives of Pathology & Laboratory Medicine (2022)
- *In the United States, Paige Prostate Detect (DEN200080) is approved for clinical use with Philips Ultrafast Scanner.
- Otherwise, all Paige Prostate Suite applications use are limited to Research Use Only and not for use in diagnostic procedures.
- In the European Union and the United Kingdom, the Paige Prostate Suite applications are approved for clinical use (CE-IVD and UKCA) with Leica Aperio AT2 and Philips Ultrafast Scanners.
